Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C). Annals of Oncology
P2.01-42 Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy
Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL
Early economic benefits of gene expression profiling using a 21-gene panel among patients with early stage, lymph node negative, hormone receptor positive, her2-neu oncogene negative breast cancer
Real-world comparative effectiveness of albumin-bound paclitaxel plus carboplatin (nab-P/C) versus solvent- based paclitaxel plus carboplatin (sb-P/C) in first-line treatment of advanced squamous cell (SCC) non-small cell lung cancer (NSCLC) in a community oncology setting
